← Stock Trading Canary · All insider profiles
INSIDER PROFILE · UK
Deborah Waterhouse
CEO, ViiV Healthcare and President, Global Health, GSK | Non-Executive Director
Profile key: uk|deborah waterhouse
Purchase history
- Companies traded
- 2
- Purchases · 12M
- 21
- Purchases · 24M
- 41
- Average purchase
- £3,792
- Gross purchase value
- £155,460
- Last purchase
- 2026-10-09
- Completed 20D events
- 31.0
- Outcome status
- PASS
Latest company: GSK plc
Companies: GSK plc | Reckitt Benckiser Group plc
Post-purchase outcomes
Benchmark-relative outcomes are available against FTSE 100.
- Excess return = stock return − FTSE 100 return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 31Established | 100.0% (31/31) | 45.2% (14/31) | -0.8% | -0.7% | -6.3% |
| 20D | 31Established | 100.0% (31/31) | 38.7% (12/31) | -2.2% | -0.5% | -12.1% |
| 60D | 28Established | 100.0% (28/28) | 42.9% (12/28) | -0.4% | +1.3% | -12.3% |
| 120D | 24Established | 100.0% (24/24) | 54.2% (13/24) | +1.1% | +2.9% | -17.3% |
Research patterns
- First purchase in 12M
- 1/33
- Large purchase ≥ €100k
- 0/33
- Cluster buying · 15D
- 33/33
- Buying the dip · ≥20% below prior 52W high
- 12/33
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.